Invivyd, Inc. Files 8-K

Ticker: IVVD · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1832038

Invivyd, INC. 8-K Filing Summary
FieldDetail
CompanyInvivyd, INC. (IVVD)
Form Type8-K
Filed DateMar 5, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: reporting, sec-filing

TL;DR

Invivyd filed a routine 8-K on 3/5/25, no major news.

AI Summary

Invivyd, Inc. filed an 8-K on March 5, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA. This filing does not appear to contain specific transactional details or financial figures beyond standard reporting information.

Why It Matters

This 8-K filing indicates Invivyd, Inc. is fulfilling its reporting obligations with the SEC, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no disclosed material events, indicating low immediate risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Invivyd, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of March 5, 2025.

When was Invivyd, Inc. formerly known as?

Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a name change date of November 12, 2020.

Where are Invivyd, Inc.'s principal executive offices located?

Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.

What is Invivyd, Inc.'s state of incorporation?

Invivyd, Inc. is incorporated in Delaware.

Does this 8-K filing disclose any specific new material events or financial transactions?

Based on the provided text, this 8-K filing appears to be a routine report and does not disclose specific new material events or financial transactions beyond standard reporting categories.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 regarding Invivyd, Inc. (IVVD).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing